Comprehensive Medical Examination: Clinical Assessment and
Patient Evaluation
2026 Edition
Question 1: A 65-year-old male presents with progressive difficulty swallowing both solids and liquids
over the past 3 months. He reports occasional regurgitation of undigested food and weight loss of 10 kg.
On examination, there is no palpable lymphadenopathy. Which of the following is the most likely
diagnosis?
A) Achalasia
B) Esophageal cancer
C) Gastroesophageal reflux disease
D) Diffuse esophageal spasm
E) Peptic stricture
ANSWER: B) Esophageal cancer
Rationale:
Option A (Incorrect): Achalasia typically presents with dysphagia to both solids and liquids from onset,
but patients usually have regurgitation of saliva and food, and weight loss is less common in early
stages. The age of presentation for achalasia is typically younger (30-60 years).
Option B (Correct): Esophageal cancer is most common in older adults (65+ years). Progressive
dysphagia starting with solids then advancing to liquids, along with significant weight loss, are hallmark
features. The absence of lymphadenopathy doesn't exclude cancer.
,Option C (Incorrect): GERD typically causes heartburn and regurgitation, with dysphagia being a less
common symptom. When present, dysphagia is usually intermittent and not progressively worsening.
Option D (Incorrect): Diffuse esophageal spasm causes intermittent chest pain and dysphagia, typically
with liquids more than solids. It does not typically cause significant weight loss.
Option E (Incorrect): Peptic strictures usually occur in patients with long-standing GERD and cause
progressive dysphagia, but patients typically have a history of heartburn and are younger than those
with esophageal cancer.
Question 2: A 45-year-old woman with rheumatoid arthritis presents with progressive shortness of
breath and dry cough over 6 months. Chest imaging shows interstitial lung disease. Which of the
following medications is most commonly associated with this complication?
A) Methotrexate
B) Sulfasalazine
C) Hydroxychloroquine
D) Etanercept
E) Tocilizumab
ANSWER: A) Methotrexate
Rationale:
Option A (Correct): Methotrexate is the most common disease-modifying antirheumatic drug (DMARD)
associated with interstitial lung disease (ILD) in rheumatoid arthritis patients. The risk increases with
cumulative dose and can occur at any time during treatment.
Option B (Incorrect): Sulfasalazine is associated with hypersensitivity reactions and pulmonary fibrosis,
but this is less common than with methotrexate. The incidence of ILD with sulfasalazine is approximately
0.1-0.5%.
,Option C (Incorrect): Hydroxychloroquine rarely causes pulmonary toxicity. It is more commonly
associated with retinal toxicity and neuromyopathy. Pulmonary complications are extremely rare.
Option D (Incorrect): Etanercept (a TNF inhibitor) can cause ILD, but the incidence is lower than with
methotrexate. When it occurs, it usually presents within the first year of treatment.
Option E (Incorrect): Tocilizumab (IL-6 inhibitor) has been associated with ILD, but the risk is lower than
with methotrexate. It is more commonly associated with neutropenia and elevated liver enzymes.
Question 3: A 72-year-old male presents with a 2-week history of headache, jaw claudication, and vision
changes in his right eye. His erythrocyte sedimentation rate is 98 mm/hr. Which of the following is the
most appropriate initial management?
A) Observation and outpatient follow-up
B) Oral prednisone 1 mg/kg/day
C) Intravenous methylprednisolone 1 g/day for 3 days
D) Tocilizumab therapy
E) Aspirin and monitoring
ANSWER: C) Intravenous methylprednisolone 1 g/day for 3 days
Rationale:
Option A (Incorrect): Observation is inappropriate given the high risk of permanent vision loss in giant
cell arteritis (GCA). This patient has classic symptoms of GCA with elevated ESR and requires immediate
intervention.
Option B (Incorrect): While oral prednisone is the mainstay of GCA treatment, for patients with visual
symptoms or impending vision loss, high-dose intravenous methylprednisolone is recommended to
rapidly achieve therapeutic levels and prevent further ischemic damage.
, Option C (Correct): Intravenous methylprednisolone (1 g/day for 3 days) is indicated in patients with
GCA who have visual symptoms. This rapid high-dose therapy can help preserve vision by quickly
reducing inflammation and preventing further ischemic events.
Option D (Incorrect): Tocilizumab is an IL-6 inhibitor approved for GCA, but it is used as a steroid-sparing
agent after diagnosis confirmation, not as initial emergency therapy in a patient with visual symptoms.
Option E (Incorrect): Aspirin may be used as an adjunct to reduce thrombotic events, but it does not
address the underlying vasculitis and is insufficient as monotherapy for GCA with visual symptoms.
Question 4: A 55-year-old man with hypertension and type 2 diabetes mellitus presents with acute-
onset right-sided weakness and difficulty speaking. His blood pressure is 185/110 mmHg. A non-contrast
head CT shows no hemorrhage. Which of the following is the most appropriate blood pressure target for
this patient if he is a candidate for thrombolysis?
A) ≤ 140/90 mmHg
B) ≤ 150/100 mmHg
C) ≤ 180/110 mmHg
D) ≤ 185/110 mmHg
E) ≤ 220/120 mmHg
ANSWER: D) ≤ 185/110 mmHg
Rationale:
Option A (Incorrect): A target of ≤ 140/90 mmHg is too low for acute ischemic stroke patients prior to
thrombolysis and could reduce cerebral perfusion to the ischemic penumbra.
Option B (Incorrect): A target of ≤ 150/100 mmHg is not the established threshold for thrombolysis
eligibility.
Patient Evaluation
2026 Edition
Question 1: A 65-year-old male presents with progressive difficulty swallowing both solids and liquids
over the past 3 months. He reports occasional regurgitation of undigested food and weight loss of 10 kg.
On examination, there is no palpable lymphadenopathy. Which of the following is the most likely
diagnosis?
A) Achalasia
B) Esophageal cancer
C) Gastroesophageal reflux disease
D) Diffuse esophageal spasm
E) Peptic stricture
ANSWER: B) Esophageal cancer
Rationale:
Option A (Incorrect): Achalasia typically presents with dysphagia to both solids and liquids from onset,
but patients usually have regurgitation of saliva and food, and weight loss is less common in early
stages. The age of presentation for achalasia is typically younger (30-60 years).
Option B (Correct): Esophageal cancer is most common in older adults (65+ years). Progressive
dysphagia starting with solids then advancing to liquids, along with significant weight loss, are hallmark
features. The absence of lymphadenopathy doesn't exclude cancer.
,Option C (Incorrect): GERD typically causes heartburn and regurgitation, with dysphagia being a less
common symptom. When present, dysphagia is usually intermittent and not progressively worsening.
Option D (Incorrect): Diffuse esophageal spasm causes intermittent chest pain and dysphagia, typically
with liquids more than solids. It does not typically cause significant weight loss.
Option E (Incorrect): Peptic strictures usually occur in patients with long-standing GERD and cause
progressive dysphagia, but patients typically have a history of heartburn and are younger than those
with esophageal cancer.
Question 2: A 45-year-old woman with rheumatoid arthritis presents with progressive shortness of
breath and dry cough over 6 months. Chest imaging shows interstitial lung disease. Which of the
following medications is most commonly associated with this complication?
A) Methotrexate
B) Sulfasalazine
C) Hydroxychloroquine
D) Etanercept
E) Tocilizumab
ANSWER: A) Methotrexate
Rationale:
Option A (Correct): Methotrexate is the most common disease-modifying antirheumatic drug (DMARD)
associated with interstitial lung disease (ILD) in rheumatoid arthritis patients. The risk increases with
cumulative dose and can occur at any time during treatment.
Option B (Incorrect): Sulfasalazine is associated with hypersensitivity reactions and pulmonary fibrosis,
but this is less common than with methotrexate. The incidence of ILD with sulfasalazine is approximately
0.1-0.5%.
,Option C (Incorrect): Hydroxychloroquine rarely causes pulmonary toxicity. It is more commonly
associated with retinal toxicity and neuromyopathy. Pulmonary complications are extremely rare.
Option D (Incorrect): Etanercept (a TNF inhibitor) can cause ILD, but the incidence is lower than with
methotrexate. When it occurs, it usually presents within the first year of treatment.
Option E (Incorrect): Tocilizumab (IL-6 inhibitor) has been associated with ILD, but the risk is lower than
with methotrexate. It is more commonly associated with neutropenia and elevated liver enzymes.
Question 3: A 72-year-old male presents with a 2-week history of headache, jaw claudication, and vision
changes in his right eye. His erythrocyte sedimentation rate is 98 mm/hr. Which of the following is the
most appropriate initial management?
A) Observation and outpatient follow-up
B) Oral prednisone 1 mg/kg/day
C) Intravenous methylprednisolone 1 g/day for 3 days
D) Tocilizumab therapy
E) Aspirin and monitoring
ANSWER: C) Intravenous methylprednisolone 1 g/day for 3 days
Rationale:
Option A (Incorrect): Observation is inappropriate given the high risk of permanent vision loss in giant
cell arteritis (GCA). This patient has classic symptoms of GCA with elevated ESR and requires immediate
intervention.
Option B (Incorrect): While oral prednisone is the mainstay of GCA treatment, for patients with visual
symptoms or impending vision loss, high-dose intravenous methylprednisolone is recommended to
rapidly achieve therapeutic levels and prevent further ischemic damage.
, Option C (Correct): Intravenous methylprednisolone (1 g/day for 3 days) is indicated in patients with
GCA who have visual symptoms. This rapid high-dose therapy can help preserve vision by quickly
reducing inflammation and preventing further ischemic events.
Option D (Incorrect): Tocilizumab is an IL-6 inhibitor approved for GCA, but it is used as a steroid-sparing
agent after diagnosis confirmation, not as initial emergency therapy in a patient with visual symptoms.
Option E (Incorrect): Aspirin may be used as an adjunct to reduce thrombotic events, but it does not
address the underlying vasculitis and is insufficient as monotherapy for GCA with visual symptoms.
Question 4: A 55-year-old man with hypertension and type 2 diabetes mellitus presents with acute-
onset right-sided weakness and difficulty speaking. His blood pressure is 185/110 mmHg. A non-contrast
head CT shows no hemorrhage. Which of the following is the most appropriate blood pressure target for
this patient if he is a candidate for thrombolysis?
A) ≤ 140/90 mmHg
B) ≤ 150/100 mmHg
C) ≤ 180/110 mmHg
D) ≤ 185/110 mmHg
E) ≤ 220/120 mmHg
ANSWER: D) ≤ 185/110 mmHg
Rationale:
Option A (Incorrect): A target of ≤ 140/90 mmHg is too low for acute ischemic stroke patients prior to
thrombolysis and could reduce cerebral perfusion to the ischemic penumbra.
Option B (Incorrect): A target of ≤ 150/100 mmHg is not the established threshold for thrombolysis
eligibility.
